Kalaris Therapeutics Incorporation Registered shs Aktie
WKN DE: A40YEN / ISIN: US4829291065
|
10.11.2026 19:16:45
|
Kalaris Therapeutics Reports Q3 Net Loss
(RTTNews) - Kalaris Therapeutics, Inc. (KLRS) on Tuesday, reported a lower net loss for the third quarter of 2026 compared with the same period in 2025, as operating expenses declined and other income remained positive.
The company posted a net loss of $11.026 million, or $0.46 per share, compared with a net loss of $11.894 million, or $0.64 per share, a year earlier.
Total operating expenses decreased to $11.811 million from $12.741 million. Research and development expenses fell to $8.344 million from $9.126 million, while general and administrative expenses declined to $3.467 million from $3.615 million.
For the first nine months of 2026, Kalaris reported a net loss of $33.397 million, or $1.40 per share, compared with a net loss of $33.440 million, or $2.41 per share, in the prior-year period. Total operating expenses increased to $36.030 million from $35.351 million.
KLRS is currently trading at $2.37, up $0.07 or 3.26 percent on the Nasdaq.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Kalaris Therapeutics Incorporation Registered shs
| Keine Nachrichten verfügbar. |